Trials / Unknown
UnknownNCT04684472
Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
Phase I, Open Label, Study of CXCR4 Modified CD19 CAR-T Therapy in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Liqun Zou · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety and tolerance of modified CD19 CAR T cells in treating refractory/relapsed B-cell malignancies. CAR-T cells will be investigated as a single agent both in relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) and up to 60% of patients with B-cell non-Hodgkin's lymphoma (NHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Modified anti-CD19 CAR T cells | intravenous infusion |
Timeline
- Start date
- 2021-03-17
- Primary completion
- 2023-01-01
- Completion
- 2024-01-01
- First posted
- 2020-12-24
- Last updated
- 2022-09-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04684472. Inclusion in this directory is not an endorsement.